Marc Husmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marc Husmann has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Barton
Molecular Internal Medicine, University of Zürich, Switzerland (M.B.).
3 shared publications Antonio Silvestro
Cardiovascular Department, Division of Clinical and Interventional Angiology, University Hospital Berne and University of Berne, Berne, Switzerland
2 shared publicationsBeatrice R. Amann-Vesti
Division of Angiology, University Hospital Zurich, Zurich, Switzerland
2 shared publicationsC. Kalka
1 shared publicationChristoph Kalka
Cardiovascular Department, Division of Clinical and Interventional Angiology, University Hospital Berne and University of Berne, Berne, Switzerland
1 shared publicationD.D. Do
1 shared publication
Latest Publications
- 1 December 2008
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 48 (6) , 1509-1513
Integrity of venoarteriolar reflex determines level of microvascular skin flow enhancement with intermittent pneumatic compression
- 1 December 2008
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 48 (6) , 1509-1513
Integrity of venoarteriolar reflex determines level of microvascular skin flow enhancement with intermittent pneumatic compression
- 1 November 2008
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 48 (5) , 1211-1216
Successful lower extremity angioplasty improves brachial artery flow-mediated dilation in patients with peripheral arterial disease
- 1 November 2008
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 48 (5) , 1211-1216
Successful lower extremity angioplasty improves brachial artery flow-mediated dilation in patients with peripheral arterial disease
- 1 July 2007
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 34 (1) , 87-91
Stenting of Common Iliac Vein Obstructions Combined with Regional Thrombolysis and Thrombectomy in Acute Deep Vein Thrombosis
- 1 July 2007
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 34 (1) , 87-91
Stenting of Common Iliac Vein Obstructions Combined with Regional Thrombolysis and Thrombectomy in Acute Deep Vein Thrombosis
- 26 April 2007
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 16 (5) , 563-567
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease
Adverse cardiovascular events are the consequence of a molecular chain reaction at the site of vulnerable plaques. Key players are platelets and coagulation factors that are activated following plaque rupture and often cause arterial obstruction. Thrombin, a plasma serine protease, plays a role in hemostasis of coagulation as well as in thrombosis and cell growth, leading to restenosis and atherosclerosis. Interesting and promising new molecules, the direct thrombin inhibitors, have been shown to be as effective as the combination of glycoprotein IIb–IIIa inhibitors and heparin for the prevention of arterial thrombosis. Until recently, direct thrombin inhibitiors could be applied only parenterally; therefore, therapy was limited to hospitalized patients. As a result of recent drug development, orally active direct thrombin inhibitors are now available and have been evaluated for the long-term treatment of venous thrombosis and arterial fibrillation. Due to their specific pharmocodynamic characteristics by binding directly to thrombin – and thus inhibiting platelet aggregation and fibrin generation – these novel drugs may also have therapeutic potential for the treatment of atherothrombotic disease and its complications such as myocardial infarction, stroke or limb ischemia.
- 26 April 2007
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 16 (5) , 563-567
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease
Adverse cardiovascular events are the consequence of a molecular chain reaction at the site of vulnerable plaques. Key players are platelets and coagulation factors that are activated following plaque rupture and often cause arterial obstruction. Thrombin, a plasma serine protease, plays a role in hemostasis of coagulation as well as in thrombosis and cell growth, leading to restenosis and atherosclerosis. Interesting and promising new molecules, the direct thrombin inhibitors, have been shown to be as effective as the combination of glycoprotein IIb–IIIa inhibitors and heparin for the prevention of arterial thrombosis. Until recently, direct thrombin inhibitiors could be applied only parenterally; therefore, therapy was limited to hospitalized patients. As a result of recent drug development, orally active direct thrombin inhibitors are now available and have been evaluated for the long-term treatment of venous thrombosis and arterial fibrillation. Due to their specific pharmocodynamic characteristics by binding directly to thrombin – and thus inhibiting platelet aggregation and fibrin generation – these novel drugs may also have therapeutic potential for the treatment of atherothrombotic disease and its complications such as myocardial infarction, stroke or limb ischemia.
- 30 November 2006
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 44 (5) , 993-997
Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
- 30 November 2006
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 44 (5) , 993-997
Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
- 1 July 2006
- Published by S. Karger AG in Journal of Vascular Research
- Vol. 43 (4) , 321-326
Postural Effects on Interstitial Fluid Pressure in Humans
Background: Direct assessment of the effect of postural changes on interstitial fluid pressure (IFP) in the human skin under physiological conditions is important for the understanding of mechanisms involved in diseases resulting in lower limb edema. Previous techniques to measure IFP had limitations of being invasive, and acute measurements were not possible. Here we describe the effect of postural changes on IFP in the skin of the foot using the minimally invasive servonulling technique. Results: Measurements were performed in 12 healthy subjects. IFP (means ± SD) was significantly higher in the sitting (5.1 ± 2.9 mm Hg) than in the supine position (–0.3 ± 3.6 mm Hg, p = 0.04) when measured in the sitting position first. The difference between the sitting and the supine position was not significant when measurements were taken in the supine position first [from 1.0 ± 4.3 (supine) to 3.6 ± 6.7 mm Hg (sitting), p = 0.46]. Spontaneous low-frequency pressure fluctuations occurred in 58% of the recordings during sitting, which was almost twice as frequent as in the supine position (33%; p = 0.001), while no effects on lymphatic capillary network extension were observed (p = 0.12). Conclusion: Using the servonulling micropressure system, postural effects on IFP can be directly assessed. IFP is higher in the sitting position, but differences are influenced by the time in the upright position.
- 1 July 2006
- Published by S. Karger AG in Journal of Vascular Research
- Vol. 43 (4) , 321-326
Postural Effects on Interstitial Fluid Pressure in Humans
Background: Direct assessment of the effect of postural changes on interstitial fluid pressure (IFP) in the human skin under physiological conditions is important for the understanding of mechanisms involved in diseases resulting in lower limb edema. Previous techniques to measure IFP had limitations of being invasive, and acute measurements were not possible. Here we describe the effect of postural changes on IFP in the skin of the foot using the minimally invasive servonulling technique. Results: Measurements were performed in 12 healthy subjects. IFP (means ± SD) was significantly higher in the sitting (5.1 ± 2.9 mm Hg) than in the supine position (–0.3 ± 3.6 mm Hg, p = 0.04) when measured in the sitting position first. The difference between the sitting and the supine position was not significant when measurements were taken in the supine position first [from 1.0 ± 4.3 (supine) to 3.6 ± 6.7 mm Hg (sitting), p = 0.46]. Spontaneous low-frequency pressure fluctuations occurred in 58% of the recordings during sitting, which was almost twice as frequent as in the supine position (33%; p = 0.001), while no effects on lymphatic capillary network extension were observed (p = 0.12). Conclusion: Using the servonulling micropressure system, postural effects on IFP can be directly assessed. IFP is higher in the sitting position, but differences are influenced by the time in the upright position.